NEW YORK, September 12, 2017 /PRNewswire/ --
If you want a Stock Review on GKOS, ELGX, MMSI, or HTGM then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Research coverage has been initiated by DailyStockTracker.com on Glaukos Corp. (NYSE: GKOS), Endologix Inc. (NASDAQ: ELGX), Merit Medical Systems Inc. (NASDAQ: MMSI), and HTG Molecular Diagnostics Inc. (NASDAQ: HTGM). These stocks are part of the Healthcare economic sector, which consists of companies that are engaged in manufacturing medical equipment, supplies, and pharmaceuticals, as well as operating healthcare facilities and provision of managed healthcare. These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at:
California headquartered Glaukos Corp.'s stock finished Monday's session 0.07% higher at $42.03. A total volume of 740,709 shares was traded, which was above their three months average volume of 530,930 shares. Over the last month and the previous three months, the Company's shares have advanced 15.75% and 7.16%, respectively. Additionally, the stock has gained 22.54% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 7.18% and 2.59%, respectively. Moreover, shares of Glaukos, which focuses on the development and commercialization of products and procedures designed to treat glaucoma, have a Relative Strength Index (RSI) of 68.44.
On August 31st, 2017, Glaukos announced that it will host an Investor Day on September 14th, 2017, beginning at 8:00 a.m. EDT and concluding at approximately 11:30 a.m. EDT in New York City. The meeting will include remarks from members of the executive team on the Company's growth strategy, pipeline technologies, and global market opportunity. A live webcast, including slide presentations, will be available on the Company's website. Your complete research report on GKOS can be retrieved for free at:
Shares in California headquartered Endologix Inc. declined 0.66%, ending yesterday's session at $4.54 with a total trading volume of 458,387 shares. The stock has gained 8.87% in the past month. The Company's shares are trading 1.76% below their 50-day moving average. Moreover, shares of Endologix, which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the US and internationally, have an RSI of 54.84.
On August 17th, 2017, Endologix announced positive interim results from the LEOPARD (Looking at Evar Outcomes by Primary Analysis of Randomized Data) clinical study. LEOPARD is the first and only head-to-head, prospective, multi-center, randomized, clinical study comparing currently available endovascular abdominal aortic stent grafts. It directly compares the Endologix AFX® and AFX2 endografts to other commercially available bifurcated aortic endografts. A free report on ELGX is just a click away at:
Merit Medical Systems
On Monday, Utah headquartered Merit Medical Systems Inc.'s stock rose 1.45%, to close the day at $42.00. A total volume of 232,793 shares was traded. The Company's shares have advanced 5.53% in the last one month, 20.34% in the previous three months, and 58.49% on an YTD basis. The stock is trading 5.40% and 30.29% above its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which designs, develops, manufactures, and markets medical products for interventional and diagnostic procedures worldwide, have an RSI of 61.95.
On August 28th, 2017, research firm Raymond James downgraded the Company's stock rating from 'Strong Buy' to 'Outperform'.
On August 29th, 2017, Merit Medical Systems announced that Chairman and CEO Fred P. Lampropoulos will host one-on-one meetings at the Credit Suisse Under Followed Opportunities Conference on September 14th, 2017, in New York City. He will also present at the Cantor Fitzgerald Healthcare Conference on September 25th, 2017, at 4:45 p.m. ET in New York City. Additionally, CFO Bernard Birkett will host one-on-one meetings at Barrington's 10th Annual Fall Conference on September 27th, 2017, in Chicago. Sign up for your complimentary research report on MMSI at:
HTG Molecular Diagnostics
Shares in Arizona-based HTG Molecular Diagnostics Inc. ended the day 1.06% higher at $1.90. A total volume of 191,638 shares was traded. The stock is trading below its 50-day moving average by 14.26%. Furthermore, shares of the Company, which develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling, have an RSI of 45.68.
On September 06th, 2017, HTG Molecular Diagnostics announced that its management will present at the Rodman and Renshaw 19th Annual Global Investment Conference on September 11th, 2017, at 5:00 p.m. ET in New York City. A live audio webcast of the presentation can be accessed under the "Investors" section of the Company's website. Register for free on DailyStockTracker.com and download the latest research report on HTGM at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.